Similarly, the most common GMT in either one of these groups (ERBB2/Her2-neu directed therapy in breast cancer; PD-1/PD-L1-targeted therapy in lung cancer) are commonly indicated and effective treatments for these two cancers. The gene discussed is ERBB2; the disease is lung carcinoma.